Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus

M. Jolly, S. Francis, R. Aggarwal, R. A. Mikolaitis, T. B. Niewold, S. Chubinskaya, J. A. Block, C. Scanzello, W. Sequeira

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current antidsDNA antibody status. Methods: Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann-Whitney test, chi square, and linear regression analyses. Results: Mean (SD) age of the patients was 44.9±12.7 years; SLEDAI (mean±SD) was 3.4±4.0. Serum lambda FLC levels had a moderate correlation (r=0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r=0.48) and SLEDAI (r=0.52) was better than of current dsDNA antibody status with PGA (r=0.33) and adjusted SLEDAI (r=0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31% of variance in SLEDAI scores. Conclusion: Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.

Original languageEnglish (US)
Pages (from-to)881-888
Number of pages8
JournalLupus
Volume23
Issue number9
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Interleukins
Interferon-alpha
Systemic Lupus Erythematosus
Light
Serum
Interleukin-6
Interleukin-10
Prostaglandins A
Antibodies
Chi-Square Distribution
Prednisone
Longitudinal Studies
Linear Models
Biomarkers
Regression Analysis
Demography

Keywords

  • biomarkers
  • free light chains (FLCs)
  • Systemic lupus erythematosus (SLE)

ASJC Scopus subject areas

  • Rheumatology

Cite this

Jolly, M., Francis, S., Aggarwal, R., Mikolaitis, R. A., Niewold, T. B., Chubinskaya, S., ... Sequeira, W. (2014). Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus, 23(9), 881-888. https://doi.org/10.1177/0961203314530793

Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. / Jolly, M.; Francis, S.; Aggarwal, R.; Mikolaitis, R. A.; Niewold, T. B.; Chubinskaya, S.; Block, J. A.; Scanzello, C.; Sequeira, W.

In: Lupus, Vol. 23, No. 9, 2014, p. 881-888.

Research output: Contribution to journalArticle

Jolly, M, Francis, S, Aggarwal, R, Mikolaitis, RA, Niewold, TB, Chubinskaya, S, Block, JA, Scanzello, C & Sequeira, W 2014, 'Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus', Lupus, vol. 23, no. 9, pp. 881-888. https://doi.org/10.1177/0961203314530793
Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S et al. Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. Lupus. 2014;23(9):881-888. https://doi.org/10.1177/0961203314530793
Jolly, M. ; Francis, S. ; Aggarwal, R. ; Mikolaitis, R. A. ; Niewold, T. B. ; Chubinskaya, S. ; Block, J. A. ; Scanzello, C. ; Sequeira, W. / Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus. In: Lupus. 2014 ; Vol. 23, No. 9. pp. 881-888.
@article{c188934ff533430db008aaf037fe0833,
title = "Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus",
abstract = "Objective: Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current antidsDNA antibody status. Methods: Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann-Whitney test, chi square, and linear regression analyses. Results: Mean (SD) age of the patients was 44.9±12.7 years; SLEDAI (mean±SD) was 3.4±4.0. Serum lambda FLC levels had a moderate correlation (r=0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r=0.48) and SLEDAI (r=0.52) was better than of current dsDNA antibody status with PGA (r=0.33) and adjusted SLEDAI (r=0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31{\%} of variance in SLEDAI scores. Conclusion: Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.",
keywords = "biomarkers, free light chains (FLCs), Systemic lupus erythematosus (SLE)",
author = "M. Jolly and S. Francis and R. Aggarwal and Mikolaitis, {R. A.} and Niewold, {T. B.} and S. Chubinskaya and Block, {J. A.} and C. Scanzello and W. Sequeira",
year = "2014",
doi = "10.1177/0961203314530793",
language = "English (US)",
volume = "23",
pages = "881--888",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus

AU - Jolly, M.

AU - Francis, S.

AU - Aggarwal, R.

AU - Mikolaitis, R. A.

AU - Niewold, T. B.

AU - Chubinskaya, S.

AU - Block, J. A.

AU - Scanzello, C.

AU - Sequeira, W.

PY - 2014

Y1 - 2014

N2 - Objective: Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current antidsDNA antibody status. Methods: Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann-Whitney test, chi square, and linear regression analyses. Results: Mean (SD) age of the patients was 44.9±12.7 years; SLEDAI (mean±SD) was 3.4±4.0. Serum lambda FLC levels had a moderate correlation (r=0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r=0.48) and SLEDAI (r=0.52) was better than of current dsDNA antibody status with PGA (r=0.33) and adjusted SLEDAI (r=0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31% of variance in SLEDAI scores. Conclusion: Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.

AB - Objective: Interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-alpha (IFN-α), and free light chains (FLCs: lambda, kappa) have all been noted to be of importance in systemic lupus erythematosus (SLE). Herein, we quantified and explored the relationship between these inflammatory mediators and disease activity in SLE; and stratified by their current antidsDNA antibody status. Methods: Seventy-seven SLE patients underwent assessment of disease activity using the SLE disease activity index (SLEDAI). Serum FLC (lambda, kappa, and total), IL-6, IL-10, and IFN-α were quantified. Demographics of disease characteristics were determined by chart reviews. Statistical analyses included Mann-Whitney test, chi square, and linear regression analyses. Results: Mean (SD) age of the patients was 44.9±12.7 years; SLEDAI (mean±SD) was 3.4±4.0. Serum lambda FLC levels had a moderate correlation (r=0.46 with physician global assessment, 0.44 with SLEDAI) and the strongest correlation with disease activity as compared with other inflammatory mediators including current dsDNA antibody status. After adjusting for prednisone use, the correlation of lambda FLC with PGA (r=0.48) and SLEDAI (r=0.52) was better than of current dsDNA antibody status with PGA (r=0.33) and adjusted SLEDAI (r=0.24), respectively. IL-10 and IFN-α activity did not correlate with disease activity. Serum FLC and IL-6 levels could differentiate between active and inactive SLE patients. Serum lambda FLC and IL-6 levels differed significantly among patients with and without current dsDNA antibodies. Serum lambda FLC levels accounted for 31% of variance in SLEDAI scores. Conclusion: Serum FLC and IL-6 are potentially useful biomarkers of disease activity in SLE. Further studies, with larger study sample and longitudinal design, are indicated.

KW - biomarkers

KW - free light chains (FLCs)

KW - Systemic lupus erythematosus (SLE)

UR - http://www.scopus.com/inward/record.url?scp=84903758257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903758257&partnerID=8YFLogxK

U2 - 10.1177/0961203314530793

DO - 10.1177/0961203314530793

M3 - Article

C2 - 24786785

AN - SCOPUS:84903758257

VL - 23

SP - 881

EP - 888

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 9

ER -